DR. JEFFREY LEYTON, PH.D.

Assistant Professor
Department of Nuclear Medicine and Radiobiology
Faculty of Medicine and Health Sciences
Université de Sherbrooke – CHUS

BIO: Dr. Leyton obtained his BSc in biochemistry from the University of California at Santa Barbara. He obtained his PhD in Molecular and Medical Pharmacology from the University of California at Los Angeles supervised by Dr. Anna Wu, a pioneer in antibody engineering. Dr. Leyton developed an engineered antibody known as a "minibody" which was advanced to clinical trial for the detection of subclinical metastases by PET imaging in men with prostate cancer. He trained as a postdoctoral fellow at the University of Toronto under the supervision of Raymond Reilly, a leading expert in radioimmunotherapeutics (RIT). Dr. Leyton was among the first to develop a RIT against cancer stem cells. He is an Assistant professor at the Université de Sherbrooke since 2013. His laboratory focuses on the development of novel subcellular transport technologies to modify and enhance the efficiency of intracellular placement and accumulation of cytotoxins delivered by antibody-drug conjugates (ADCs) in target tumor cells. He has been an award scholar of the American Association for Cancer Research and the Canadian Banting Research Foundation.

PRESENTATION TITLE: ***ADCs with integrated endosome escape and nuclear-directional intracellular trafficking-control capabilities – An approach for next-generation cancer therapeutics***